Skip to main content
GlaxoSmithKline PLC logo

GlaxoSmithKline PLC — Investor Relations & Filings

Ticker · GSK ISIN · GB00BN7SWP63 LEI · 5493000HZTVUYLO1D793 IL Manufacturing
Open in API
Filings indexed 7,016 across all filing types
Latest filing 2026-02-27 Director's Dealing
Country GB United Kingdom
Listing IL GSK

About GlaxoSmithKline PLC

https://www.gsk.com/en-gb/

GSK plc is a global biopharmaceutical company that unites science, technology, and talent to research, develop, and manufacture medicines and vaccines. The company focuses on preventing and treating disease across four primary therapeutic areas: infectious diseases, HIV, oncology, and immunology/respiratory. Its portfolio consists of specialty medicines and vaccines aimed at addressing significant global health needs. GSK's strategy centers on leveraging its research and development capabilities to deliver new health solutions.

Recent filings

Filing Released Lang Actions
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a formal notification of a transaction by a Person Discharging Managerial Responsibilities (PDMR), specifically Maya Martinez-Davis, President of US at GSK plc. It details the acquisition of American Depositary Shares (ADS) through a dividend reinvestment plan. This type of disclosure is a standard regulatory requirement for insider/director dealings, which falls under the 'Director's Dealing' category.
2026-02-27 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is a formal announcement from GSK plc regarding the purchase of its own shares (a share buyback program). It details the date of purchase, the number of shares acquired, the price paid, and the impact on treasury shares and total voting rights. This aligns perfectly with the definition of 'Transaction in Own Shares' (POS).
2026-02-27 English
Linerixibat accepted for priority review in China
Regulatory Filings Classification · 95% confidence The document is a press release from GSK plc announcing that their drug linerixibat has been accepted for priority review in China. It discusses clinical trial data, regulatory review status, and provides background on the drug and company. There are no financial statements, no detailed financial performance data, no management discussion of financial results, and no regulatory certifications or filings. The document is an announcement of a regulatory milestone and clinical development update, typical of a Regulatory Filing (RNS) rather than a financial report or other specific filing type. The length is moderate (6761 characters), but the content is clearly a regulatory announcement rather than a report or presentation. Therefore, the appropriate classification is Regulatory Filings (RNS).
2026-02-26 English
Bepirovirsen accepted for Japan regulatory review
Regulatory Filings Classification · 95% confidence The document is a press release from GSK plc announcing that Japan's Ministry of Health, Labour and Welfare has accepted for review a new drug application (NDA) for bepirovirsen, a treatment for chronic hepatitis B. It details clinical trial results, regulatory designations, and the significance of the drug. The document is an announcement of a regulatory submission and clinical development update, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis. It is a regulatory announcement about a drug approval process and clinical trial results, fitting best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2026-02-26 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is a detailed announcement from GSK plc about the purchase of its own shares through a buyback program. It includes specific transaction details such as dates, number of shares purchased, prices paid, and trading venues. The content focuses on the company's repurchase of its own shares and treasury share holdings. There is no indication of financial statements, management discussion, or other report types. The document is not a report publication announcement but a direct disclosure of share repurchase transactions. Therefore, it fits the category of Transaction in Own Shares (POS). The document length is substantial and contains detailed transactional data, supporting a high confidence classification.
2026-02-26 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document is a transaction notification related to a personal dealing by a person closely associated with the company (Chief People Officer) acquiring American Depositary Shares under a pension plan. It includes details such as the name of the person, position, transaction type, price, volume, date, and place of transaction. There is no financial report, earnings data, or management discussion. The document is a regulatory announcement of insider share transactions by a company director or executive. Therefore, it fits the category of Director's Dealing (DIRS). The document length is short and focused solely on the transaction notification, confirming this classification with high confidence.
2026-02-25 English

Browse filings by year

27 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.